Physician profile
Cara Doogan
NPI 1770930521
$1,069.03
in general payments reported to CMS, 2019-2025
14 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.32 · 2023: $359 · 2024: $482 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $392.94 | 2023-2024 | Localizer, Mammosite, Biozorb |
| Daiichi Sankyo INC. | $157.93 | 2022-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $141.92 | 2023-2025 | Enhertu, Lynparza, Tagrisso |
| Novartis Pharmaceuticals Corporation | $94.46 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $55.73 | 2023-2025 | Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $54.10 | 2024-2025 | |
| Abbvie INC. | $34.12 | 2025 | |
| Alexion Pharmaceuticals, INC. | $30.70 | 2024 | Ultomiris |
| Eisai INC. | $22.88 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.98 | 2024 | Alunbrig |
| Incyte Corporation | $17.64 | 2025 | Zynyz, Monjuvi |
| Genmab U.S., INC. | $16.43 | 2024 | Epkinly |
| Jazz Pharmaceuticals INC. | $15.05 | 2024 | |
| Seagen INC. | $14.15 | 2023 | Adcetris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Doogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.